16081-47-3

Basic information

• Product Name: 7-bromo-2,3-dihydro-benzo[1,4]dioxin-5-ylamine
• CAS NO: 16081-47-3
• Molecular Weight: 230.061
• Mol File: 16081-47-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 7-bromo-2,3-dihydro-benzo[1,4]dioxin-5-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromo-2,3-dihydro-benzo[1,4]dioxin-5-ylamine(16081-47-3)
• EPA Substance Registry System: 7-bromo-2,3-dihydro-benzo[1,4]dioxin-5-ylamine(16081-47-3)

Safety Data

• Hazardous Substances Data: 16081-47-3(Hazardous Substances Data)

Upstream product

• 671779-99-0 1-nitro-2,3-dihydroxy-5-bromobenzene 
• 16634-88-1 5-bromo-3-nitrosalicylaldehyde 
• 1761-61-1 5-bromosalicyclaldehyde 
• 69464-52-4 7-bromo-5-nitro-2,3-dihydrobenzo[b][1,4]dioxine 

Relevant articles and documents

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold

Receptor-interacting protein kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors bas

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS

Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:wherein A, R1, R2, R3, p, q, A and X are as defined in the specification. Preparation of the compounds and uses in the treatment of CNS and other disorders, including dep